Ascendis Reports Second Quarter 2017 Financial Results
COPENHAGEN, Denmark, Aug. 18, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced financial results for the quarter ended June 30, 2017.
“We are making excellent progress executing our Vision 20/20 strategic plan to establish Ascendis as a leading, integrated rare disease company,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer. “Our phase 3 heiGHt trial for TransCon Growth Hormone is well underway and on track to be fully enrolled in the fourth quarter. We are now transitioning to having two product candidates in clinical development: TransCon Growth Hormone and TransCon PTH. Additionally, early next year we expect to initiate clinical development of our third product candidate, TransCon CNP. All three of our rare disease endocrinology product candidates are designed to make a meaningful impact in patients’ lives while addressing significant market opportunities.”
“We are making excellent progress executing our Vision 20/20 strategic plan to establish Ascendis as a leading, integrated rare disease company,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer. “Our phase 3 heiGHt trial for TransCon Growth Hormone is well underway and on track to be fully enrolled in the fourth quarter. We are now transitioning to having two product candidates in clinical development: TransCon Growth Hormone and TransCon PTH. Additionally, early next year we expect to initiate clinical development of our third product candidate, TransCon CNP. All three of our rare disease endocrinology product candidates are designed to make a meaningful impact in patients’ lives while addressing significant market opportunities.”